Published in Cancer Weekly, November 27th, 2001
The decrease in net loss is attributed to THERATOPE vaccine and vaccine licensing revenues and product development reimbursements received from Merck KGaA, Biomira's collaborator for these vaccines. Research and development expenditures for the nine months ended September 30, 2001 totaled $30.6 million compared with $31.2 million for the same period in 2000.
During the third quarter, Biomira raised...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.